{"id":{"repo_id":"cape-town","oai_identifier":"oai:open.uct.ac.za:11427/4321"},"canonical_url":"https://search.dev.ndltd.org/etd/cape-town/oai:open.uct.ac.za:11427/4321","repository":{"repo_id":"cape-town","name":"University of Cape Town","base_url":"https://open.uct.ac.za/oai/request"},"display":{"title":"Optimization of chimaeric HIV-1 virus-like particle (VLP) production and immunogenicity testing of VLPs in mice","abstract":"The devastating effect the HIV pandemic has had on the human population in the last twenty five years has highlighted the great need to develop a prophylactic HIV vaccine. The manufacture of a vaccine has proven difficult though, with a number of successful designs in animal models having little success in humans. In view of this, there has been a need for novel vaccine approaches that are able to elicit effective cellular and humoral immune responses, both of which are believed to be important in the eradication of the virus. One such approach is the use of HIV-1 Gag VLPs as vaccine candidates. In this study, the production of two chimaeric (Gag VLP vaccine candidates (GagRT and GagTN) was optimized in insect cells, and their ability to enhance a murine immune response in a DNA prime-VLP boost vaccine strategy was evaluated.","abstract_html":"The devastating effect the HIV pandemic has had on the human population in the last twenty five years has highlighted the great need to develop a prophylactic HIV vaccine. The manufacture of a vaccine has proven difficult though, with a number of successful designs in animal models having little success in humans. In view of this, there has been a need for novel vaccine approaches that are able to elicit effective cellular and humoral immune responses, both of which are believed to be important in the eradication of the virus. One such approach is the use of HIV-1 Gag VLPs as vaccine candidates. In this study, the production of two chimaeric (Gag VLP vaccine candidates (GagRT and GagTN) was optimized in insect cells, and their ability to enhance a murine immune response in a DNA prime-VLP boost vaccine strategy was evaluated.","abstract_has_math":false,"creators":["Pillay, Sirika"],"institution":"Department of Molecular and Cell Biology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Rybicki, Ed","Meyers, Ann"],"committee_chairs":[],"committee_members":[],"year":2008,"date_issued":"2008","date_published":"2008","updated_at":"2026-07-22T22:22:51Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11427/4321","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Rybicki, Ed","Meyers, Ann"]},{"key":"dc:creator","label":"Author","values":["Pillay, Sirika"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-07-30T17:41:38Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-07-30T17:41:38Z"]},{"key":"dc:date.issued","label":"Date","values":["2008"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Department of Molecular and Cell Biology"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Cape Town"]},{"key":"dc:type","label":"Dc Type","values":["Master Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Masters"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["MSc"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11427/4321"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Includes abstract.","Includes bibliographical references (leaves 139-148)."]},{"key":"dc:description.abstract","label":"Abstract","values":["The devastating effect the HIV pandemic has had on the human population in the last twenty five years has highlighted the great need to develop a prophylactic HIV vaccine. The manufacture of a vaccine has proven difficult though, with a number of successful designs in animal models having little success in humans. In view of this, there has been a need for novel vaccine approaches that are able to elicit effective cellular and humoral immune responses, both of which are believed to be important in the eradication of the virus. One such approach is the use of HIV-1 Gag VLPs as vaccine candidates. In this study, the production of two chimaeric (Gag VLP vaccine candidates (GagRT and GagTN) was optimized in insect cells, and their ability to enhance a murine immune response in a DNA prime-VLP boost vaccine strategy was evaluated."]},{"key":"dc:title","label":"Title","values":["Optimization of chimaeric HIV-1 virus-like particle (VLP) production and immunogenicity testing of VLPs in mice"]}]}],"canonical_facts":{"dc:contributor.advisor":["Rybicki, Ed","Meyers, Ann"],"dc:creator":["Pillay, Sirika"],"dc:date.accessioned":["2014-07-30T17:41:38Z"],"dc:date.available":["2014-07-30T17:41:38Z"],"dc:date.issued":["2008"],"dc:description":["Includes abstract.","Includes bibliographical references (leaves 139-148)."],"dc:description.abstract":["The devastating effect the HIV pandemic has had on the human population in the last twenty five years has highlighted the great need to develop a prophylactic HIV vaccine. The manufacture of a vaccine has proven difficult though, with a number of successful designs in animal models having little success in humans. In view of this, there has been a need for novel vaccine approaches that are able to elicit effective cellular and humoral immune responses, both of which are believed to be important in the eradication of the virus. One such approach is the use of HIV-1 Gag VLPs as vaccine candidates. In this study, the production of two chimaeric (Gag VLP vaccine candidates (GagRT and GagTN) was optimized in insect cells, and their ability to enhance a murine immune response in a DNA prime-VLP boost vaccine strategy was evaluated."],"dc:identifier.uri":["http://hdl.handle.net/11427/4321"],"dc:language.iso":["eng"],"dc:publisher.department":["Department of Molecular and Cell Biology"],"dc:publisher.institution":["University of Cape Town"],"dc:title":["Optimization of chimaeric HIV-1 virus-like particle (VLP) production and immunogenicity testing of VLPs in mice"],"dc:type":["Master Thesis"],"dc:type.qualificationlevel":["Masters"],"dc:type.qualificationname":["MSc"]},"updated_at":"2026-07-22T22:22:51Z"}